News

RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

January 18, 2023

RenovoRx today announced initial results from a pharmacokinetic (PK) substudy within the phase III un-blinded randomized control TIGeR-PaC clinical trial to be presented at the 2023 ASCO Gastrointestinal (ASCO GI)…

RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent

January 5, 2023

RenovoRx today announced that on January 3, 2023 the United States Patent and Trademark Office issued US patent number 11,541,211 broadly covering methods for treating cholangiocarcinoma (bile duct cancer) by…

RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium

December 15, 2022

RenovoRx today announced the acceptance of four clinical data abstracts supporting its lead oncology product candidate, RenovoGem, and its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform to be presented at…

RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers

November 17, 2022

RenovoRx today announced RenovoTAMP was highlighted in two presentations delivered at the Advanced Interventional Management Symposium (AIMsymposium). RenovoTAMP is a unique therapy platform designed for targeted intra-arterial (IA) delivery of…

RenovoRx Reports Third Quarter 2022 Financial Results

November 14, 2022

RenovoRx today reported its financial results for the quarter ended September 30, 2022.

RenovoRx to Participate in Upcoming October 2022 Investor Conferences

October 4, 2022

RenovoRx today announced management’s participation in two upcoming investor conferences this month. Conferences include ROTH Inaugural Healthcare Opportunities, October 6th, and LD Micro Main Event XV, October 25th-27th.

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer

September 28, 2022

RenovoRx today announced Ripal Gandhi, M.D., FSIR, FSVM presented, “Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer,” at the recent Symposium on Clinical Interventional Oncology (CIO). Dr. Gandhi is a course director…

RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer

September 19, 2022

RenovoRx today announced that Angela Gill Nelms has joined the company as Chief Operating Officer (“COO”).

RenovoRx Reports Second Quarter 2022 Financial Results

August 15, 2022

RenovoRx today reported its financial results for the quarter ended June 30, 2022.

RenovoRx Appoints James Ahlers as Chief Financial Officer and Expands Finance Team with Addition of Ronald B. Kocak, CPA as Vice President and Controller

July 19, 2022

RenovoRx today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller…

RenovoRx Launches “The RenovoRx Story” Video Series Spotlighting the RenovoRx Journey, its Leadership and Innovative Treatment Platform Targeting Difficult-to-Treat Cancers

July 11, 2022

RenovoRx today announced the launch of a new video series – The RenovoRx Story. This video series provides viewers with a unique opportunity to learn more about the Company, its…

RenovoRx and TigeR-PaC Leadership to Host RenovoTAMP® Webinar on June 21, 2022

June 9, 2022

RenovoRx today announced that they will host a webinar highlighting their RenovoTAMP® therapy platform. The webinar, “Facing Today’s Challenges in Pancreatic Cancer Treatment: Understanding RenovoRx’s Trans-Arterial Micro-Perfusion Therapy Platform,” will…

* Individual results may vary.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.